|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Product revenue, net | |||||
| Operating expenses | |||||
| Cost of goods sold | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Litigation settlement | |||||
| Total operating expenses | |||||
| Income (loss) from operations | |||||
| Other income | |||||
| Gain from sale of priority review voucher | |||||
| Interest expense | |||||
| Interest and other income, net | |||||
| Income before income taxes | |||||
| Income tax benefit (expense) | |||||
| Net income | |||||
| Unrealized gain (loss) on available-for-sale securities, net of tax | |||||
| Foreign currency translation | |||||
| Comprehensive income | |||||
| Net income per common share: | |||||
| Basic (in usd per share) | |||||
| Diluted (in usd per share) | |||||
| Weighted-average common shares outstanding: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...
